Javitt Jonathan C
Known title: Chief ScientistCIK: 0001303782
Javitt Jonathan C's purchase track record
How the stock did after each of Javitt Jonathan C's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since June 1, 2022
Stock higher 6 months later
100%
3 months: 67%
Median 6-month return
+103.7%
3 months: +13.6%
Beat the S&P 500
100%
median +104.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/17/2024 | NRXP | $47K | +34.2% | +103.7% | -1.1% |
| 8/22/2023 | NRXP | $97K | -2.6% | +49.0% | +13.4% |
| 6/1/2022 | NRXP | $5.80M | +13.6% | +151.8% | -0.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NRXP | ▲ Buy | Open Market | 40,000 | $47K | 12/17/2024 | View on chart |
| NRXP | ▲ Buy | Open Market | 100,000 | $33K | 8/23/2023 | View on chart |
| NRXP | ▲ Buy | Open Market | 200,000 | $64K | 8/22/2023 | View on chart |
| NRXP | ▼ Sell | Open Market | 400,000 | $400K | 12/7/2022 | View on chart |
| NRXP | ▲ Buy | Open Market | 100,000 | $5.8M | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership
Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership. Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.